RxDoctor Payments Data

Loretta Opila, MD

Emergency Medicine · Johnstown, PANPI 1932178894

Payments from drug & device makers

$671in general payments, 2019–2025

Across 29 payments — averaging $23.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$257
  • Alkermes, Inc.$134
  • Otsuka America Pharmaceutical, Inc.$101
  • Lilly USA, LLC$87
  • Johnson & Johnson$33
  • Sanofi Pasteur Inc.$27
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$671100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$671 in reported general payments places this provider in the 90th percentile of 3,120 emergency medicine providers in Pennsylvania.

See all emergency medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$2,032
Medicare patients
11
Services billed
26

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol38$33,051
TrulicityDulaglutide22$20,459
XareltoRivaroxaban17$19,434
VivitrolNaltrexone Microspheres11$17,688
Trelegy ElliptaFluticasone/Umeclidin/Vilanter20$14,061
JardianceEmpagliflozin11$12,505
EntrestoSacubitril/Valsartan12$9,671
Breo ElliptaFluticasone/Vilanterol11$4,405
Aripiprazole15$3,691
Albuterol Sulfate HfaAlbuterol Sulfate102$2,345
Gabapentin86$1,605
Duloxetine Hcl46$1,308
Atorvastatin Calcium99$1,081
Oxycodone Hcl30$932
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine15$850

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity$87$20,45922 claims
Johnson & JohnsonXarelto$33$19,43417 claims
Alkermes, Inc.Vivitrol$134$17,68811 claims
NovartisEntresto$18$9,67112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,120 emergency medicine providers in Pennsylvania.

Other emergency medicine in Johnstown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →